Authors
Latest:
Treatment Options for Multicentric Castleman's DiseaseFrits van Rhee, MD, PhD, MRCP, professor of medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, discusses treatment options for multicentric Castleman's disease.
Latest:
Results of the MONALEESA-2 Study in Advanced Breast CancerGabriel Hortobagyi, MD, professor of Medicine, University of Texas, MD Anderson Cancer Center, discusses the major findings of the MONALEESA-2 study in advanced breast cancer, during an interview at the 2016 ESMO Congress.
Latest:
A Study of Nivolumab With Nab-Paclitaxel Plus Gemcitabine in Pancreatic CancerGabriela Chiorean, MD, professor of medicine, discusses an ongoing phase I study of nivolumab with nab-paclitaxel plus gemcitabine in pancreatic cancer.
Latest:
Unmet Needs Remain in Treating Post-MPN Acute LeukemiaGabriela Hobbs, MD, discusses the unmet needs that have yet to be filled in the post-myeloproliferative neoplasm acute leukemia space.
Latest:
FLT3 Inhibitors Impact Treatment Landscape for Patients With FLT3-Mutated AMLGail Roboz, MD, discusses the use of FLT3 inhibitors as treatment of patients with acute myeloid leukemia, which can be a heterogenous and difficult-to-treat disease. There is a lot of optimism for new drugs and targets in AML, but the disease itself remains tough to treat, according to Roboz.
Latest:
Evaluating the Role of CAR T Cells in Multiple MyelomaGareth Morgan, MD, discusses where he sees the field headed for the treatment of patients with multiple myeloma.
Latest:
Gene Expression Profiling for Smoldering Myeloma PatientsGareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses gene expression profiling for patients with smoldering myeloma.
Latest:
How Oncologists Can Benefit From New AUA Guidelines in Bladder CancerGary D. Steinberg, MD, discusses how medical oncologists can benefit from the new American Urological Association guidelines when treating bladder cancer.
Latest:
Results for HS-410 Vaccine in Non-Muscle Invasive Bladder CancerGary Steinberg, MD, director, Urologic Oncology, The University of Chicago Medicine, discusses the immune response results of vesigenurtacel-I (HS-410) vaccine in non-muscle invasive bladder cancer.
Latest:
Acquired Resistance to Osimertinib in T790M-Positive NSCLCGeoffrey R. Oxnard, MD, discusses a study that found overgrowth of competing resistance mechanisms, such as an acquired <em>KRAS</em> mutation, underlies a poor prognosis subtype of acquire resistance to osimertinib in T-790M-positive non-small cell lung cancer.
Latest:
Dr. Geoffrey Shapiro on the Role of CDK2 in Multiple Breast Cancer TypesGeoffrey Shapiro, MD, PhD, director, Early Drug Development Center, Dana Farber, discusses the role of cyclin-dependent kinase (CDK4) in some breast cancer subtypes and the lack of targeted agents in triple-negative breast cancer.
Latest:
The Possibility for Immunotherapy in Neoadjuvant Bladder Cancer TreatmentGeoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the possibility for immunotherapy as a neoadjuvant treatment in bladder cancer.
Latest:
The Future of Immune Checkpoint Inhibition in Gastric and Esophageal CancersGeoffrey Y. Ku, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future of immune checkpoint inhibition in gastric and esophageal cancers.
Latest:
Breaking Down Sarcoma, Other Cancers Into Different TypesGeorge D. Demetri, MD, senior vice president for Experimental Therapeutics at the Dana-Farber Cancer Institute, professor of Medicine at Harvard Medical School, and co-director of the Ludwig Center at Harvard, discusses how sarcoma is leading the way in the breakdown of cancers into different types.
Latest:
Dr. George Demetri on the Mutagenic Properties and Future Potentials of DacarbazineGeorge Demetri, MD, professor of medicine, Harvard Medical School, director of the Sarcoma Center, Dana Farber Brigham Women's Cancer Center, on the mutagenic properties of dacarbazine.
Latest:
Regorafenib in the Treatment of Colorectal CancerRegorafenib is a recently approved oral, multikinase inhibitor for refractory colorectal cancer. Although structurally similar to sorafenib, it more potently inhibits a broader spectrum of critical growth receptor pathways, including those regulating angiogenesis and aberrant cellular proliferation.
Latest:
Overall Survival Data of the MONARCH-2 Trial in HR+/HER2- Breast CancerGeorge Sledge, Jr., MD, discusses the overall survival data of the phase III MONARCH-2 trial in advanced hormone receptor-positive, HER2-negative breast cancer.
Latest:
Recent Advancements in Multiple MyelomaGeorge Somlo, MD, medical oncologist, City of Hope, discusses recent advancements in multiple myeloma treatment.
Latest:
The Mechanisms of Resistance in Breast CancerGeorge W. Sledge, Jr, MD, Chief, Division of Oncology, Professor of Medicine, Stanford University School of Medicine, discusses the mechanisms of resistance in breast cancer.
Latest:
Dr. Georgia L. Wiesner on the Importance of Genetic Testing for Colorectal CancerGeorgia L. Wiesner, MD, MS, director, Clinical and Translational Hereditary Cancer Program, Ingram Professor of Cancer Research, professor of Medicine, cancer geneticist, Vanderbilt-Ingram Cancer Center, discusses the role genetic testing for colorectal cancer (CRC) plays in families.
Latest:
Targeted Therapies in Development for MelanomaGeorgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, highlights targeted therapies in development for melanoma.
Latest:
Patients in CheckMate 067 Demonstrate Durable Complete ResponsesGeorgina V. Long, BSc, PhD, MBBS, discusses the response rates in the CheckMate 067 trial, which evaluated the combination of ipilimumab and nivolumab in patients with advanced melanoma.
Latest:
Combination Nivolumab and Ipilimumab Shows Efficacy in Advanced MelanomaGeorgina V. Long, BSc, PhD, MBBS, FRACP, discusses the design and efficacy of the phase III CheckMate 067 trial for patients with advanced melanoma.<br />
Latest:
Explaining Synergy in the Olaparib/Neratinib Combination for Uterine Serous CarcinomasGhanshyam Yadav, MD, a first-year resident in Obstetrics Gynecology & Reproductive Services, Baylor College of Medicine, talks through the results of a preclinical trial that found synergy in the combination of the PARP inhibitor olaparib and the pan-HER tyrosine kinase inhibitor neratinib for uterine serous cancers that overexpress HER2.
Latest:
Exploring Tislelizumab for Unresectable HCCGhassan K. Abou-Alfa, MD,discusses the phase 2 study of tislelizumab in patients with unresectable hepatocellular carcinoma.
Latest:
Phase 3 RATIONALE-301 Study Evaluates Tislelizumab vs Sorafenib in HCCGhassan K. Abou-Alfa, MD, discusses the phase 3 RATIONALE-301 trial of frontline tislelizumab vs sorafenib in patients with hepatocellular carcinoma.
Latest:
Targeting HRAS Mutations With Investigational Tipifarnib May Hold Promise in Some Tumor TypesThe high variability in responses among different types of HRAS-altered cancers highlights the need to identify rational therapeutic combinations that enhance response to HRAS-directed therapies.
Latest:
Garon Sheds Light on Next Steps With EGFR-Targeted Agents in NSCLCEdward B. Garon, MD, discusses the role of EGFR-targeted therapies in the treatment landscape of NSCLC.
Latest:
Neoadjuvant Therapy Impresses in I-SPY 2 Trial for Breast CancerAccording to investigators on the phase 2 I-SPY 2 study, the addition durvalumab plus olaparib to treatment with neoadjuvant paclitaxel led to better pathologic complete response rates in patients with high-risk, HER2-negative stage II/III breast cancer compared with paclitaxel alone.
